



CASE PH7087A CIP

1653
JRWCERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Debra A. Wojcik
Type or print name

Debra A. Wojcik
Signature

May 13, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1653

PRIESTLEY ET AL.

Examiner: David Lukton

APPLICATION NO: 10/010,184

FILED: DECEMBER 6, 2001

FOR: NOVEL LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES

This is in response to the Office Action mailed April 23, 2004 wherein the claims were restricted into two groups:

- I. Claims 1 to 17 drawn to compounds
- II. Claims 18-26, drawn to methods of using compounds

Applicants elect the claims of Group 1 and furthermore, the species shown by Example 10, (1R)-1-(((2S)-3-cyclohexyl-2-(3-isopropyl-3-(((3-methylphenyl)sulfonyl)amino)-2-oxo-1-pyrrolidinyl)propanoyl)amino)propylboronic acid. Claims 1 to 17 are readable upon the elected species.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3453

Date: May 13, 2004

Maureen S. Gibbons
Maureen S. Gibbons
Attorney for Applicants
Reg. No. 44,121